Simu K. Thomas

1.9k total citations
56 papers, 1.5k citations indexed

About

Simu K. Thomas is a scholar working on Pediatrics, Perinatology and Child Health, Psychiatry and Mental health and Genetics. According to data from OpenAlex, Simu K. Thomas has authored 56 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pediatrics, Perinatology and Child Health, 14 papers in Psychiatry and Mental health and 13 papers in Genetics. Recurrent topics in Simu K. Thomas's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Hemoglobinopathies and Related Disorders (10 papers). Simu K. Thomas is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Hemoglobinopathies and Related Disorders (10 papers). Simu K. Thomas collaborates with scholars based in United States, United Kingdom and Switzerland. Simu K. Thomas's co-authors include Jean‐François Baladi, Thomas E. Delea, Pradyumna D. Phatak, Oleg Sofrygin, Thomas D. Coates, Roger Lane, Weiwei Feng, George A. Goldberg, Jörge E. Cortes and Alan K. Hatfield and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Simu K. Thomas

54 papers receiving 1.4k citations

Peers

Countries citing papers authored by Simu K. Thomas

Since Specialization

Citations

This map shows the geographic impact of Simu K. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simu K. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simu K. Thomas more than expected).

Fields of papers citing papers by Simu K. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simu K. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simu K. Thomas. The network helps show where Simu K. Thomas may publish in the future.

Co-authorship network of co-authors of Simu K. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Simu K. Thomas. A scholar is included among the top collaborators of Simu K. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simu K. Thomas. Simu K. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HTA Evidence in Rare Diseases: Just Rare or Also Special? 2025 ·PharmacoEconomics ·(unknown), Simu K. Thomas, Richard H. Chapman, (unknown)	1
2	Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria 2020 ·PharmacoEconomics ·(unknown), Marric Buessing, Scott J. Johnson, (unknown), Simu K. Thomas, Ioannis Tomazos	18
3	PRO33 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2019 ·Value in Health ·(unknown), Marric Buessing, (unknown), (unknown), Ioannis Tomazos, Simu K. Thomas	1
4	A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis 2014 ·Value in Health ·S. Bhattacharyya, (unknown), (unknown), (unknown), (unknown), Patrick A. Flume, (unknown), Simu K. Thomas	0
5	Long-Term Costs and Consequences of Patients with Familial Chylomicronemia Syndrome – A Simulation Model Approach 2014 ·Value in Health ·Feng Lin, Simu K. Thomas, (unknown), (unknown)	4
6	The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective 2014 ·Value in Health ·Minal Jain, (unknown), (unknown), Simu K. Thomas, Patrick Mollon	2
7	Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial 2012 ·British Journal of Ophthalmology ·Paul Mitchell, Lieven Annemans, Meghan Gallagher, (unknown), Simu K. Thomas, Kerry Gairy, (unknown), (unknown)	62
8	Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration 2011 ·PharmacoEconomics ·Paul Mitchell, Lieven Annemans, Richard G. White, Meghan Gallagher, Simu K. Thomas	43
9	Predicting time to nursing home placement based on activities of daily living scores – a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil 2009 ·Journal of Medical Economics ·Hind T. Hatoum, Simu K. Thomas, (unknown), Roger Lane, Roger Bullock	35
10	Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease 2007 ·International Journal of Geriatric Psychiatry ·Bengt Winblad, Ariane K. Kawata, Kathleen Beusterien, Simu K. Thomas, Anders Wimo, Roger Lane, Howard Fillit, Rafael Blesa	86
11	Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs 2007 ·PharmacoEconomics ·Theodore Darkow, Henry J. Henk, Simu K. Thomas, Weiwei Feng, Jean‐François Baladi, George A. Goldberg, Alan K. Hatfield, Jörge E. Cortes	233
12	Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients 2007 ·PharmacoEconomics ·Thomas E. Delea, Oleg Sofrygin, Simu K. Thomas, Jean‐François Baladi, Pradyumna D. Phatak, Thomas D. Coates	70
13	Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase Inhibitors 2006 ·Clinical Breast Cancer ·Betty A. Mincey, Mei Sheng Duh, Simu K. Thomas, Érick Moyneur, (unknown), Simone Peart Boyce, David Mallett, Edith A. Perez	72
14	The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer’s Disease 2005 ·Journal of the American Medical Directors Association ·Hind T. Hatoum, Swu‐Jane Lin, Stephen Arcona, Simu K. Thomas, Barbara Koumaras, Dario Mirski	13
15	Drug Persistency of Two Cholinesterase Inhibitors 2005 ·Drugs & Aging ·Dong‐Churl Suh, Simu K. Thomas, Elmira Valiyeva, Stephen Arcona, Lien Vo	44
16	Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder 2005 ·Epilepsy & Behavior ·Won Chan Lee, Steve Arcona, Simu K. Thomas, Qin Wang, Marc Hoffmann, Chris L. Pashos	36
17	Gastrointestinal Adverse Events in a General Population Sample of Nursing Home Residents Taking Cholinesterase Inhibitors 2004 ·The Consultant Pharmacist ·Anthony J. Hughes, (unknown), Simu K. Thomas, Kathleen Beusterien, (unknown), Stephen Arcona	7
18	Use of ICD‐9 coding as a proxy for stage of disease in lung cancer 2002 ·Pharmacoepidemiology and Drug Safety ·Simu K. Thomas, Sandra E. Brooks, C. Daniel Mullins, Claudia R. Baquet, Sanjay Merchant	25
19	Association of Knowledge, Anxiety, and Fear with Adherence to Follow Up for Colposcopy 2002 ·Journal of Lower Genital Tract Disease ·Sandra E. Brooks, (unknown), (unknown), Simu K. Thomas, (unknown), (unknown)	31
20	Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin converting enzyme inhibition 1998 ·Journal of the American College of Cardiology ·Glenn S. Hamroff, (unknown), (unknown), Stephen A. Katz, Rachel Bijou, Guillaume Jondeau, M. T. Olivari, Simu K. Thomas, Thierry H. LeJemtel	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact